FOR ALL YOUR SUPERFICIAL SKIN PROCEDURES

Advanced liposomal formulation4,5

• Facilitates the rate and extent of penetration• Enhances the onset of action• Helps reduce metabolic breakdown

Prescribing InformationPlease review full Product Information before prescribing. Full Product Information is available from Dermocosmética.

LMX4 PRESCRIBING INFORMATION:Indications: For topical anaesthesia of intact skin prior to superficial skin procedures, including IV cannulation and blood sampling. Do not apply to large areas of the body except on the advice of a healthcare practitioner. Directions For Use: See pack insert for detailed instructions. Apply a small amount and massage in if not using an occlusive dressing. Cover the area to be anaesthetised with a thick layer of cream and cover if required with an occlusive dressing. Wait for at least 30 minutes for the anaesthetic to take effect. If skin irritation occurs stop immediately and seek medical attention. For external use only. Also contains benzyl alcohol as a preservative. DO NOT APPLY NEAR EYES. NOT TO BE USED ON BROKEN SKIN. Store below 25°C.

PBS Information: This product is not listed on the PBS

Epidermis

Dermis

TIME OF ONSET

ERYTHEMA INCIDENCE

STORAGE CONDITIONS

30 mins2,3,6 Low1,2 Below 25°C

emla® 60 mins7 Low1 Below 25°C

Tetracaine/Amethocaine

30–45 mins8 High1,8 Refrigerate

Distributed in Australia and New Zealand by Dermocosmètica ABN 52152881019 88 Mount Alexander Road Flemington VIC 3031 AUSTRALIA T: +61 3 9386 3503 F: +61 3 8692 6923 E: lmx4@dermocosmetica.com.au W: dermocosmetica.com.au

Copyright © Dermocosmètica 2012. All rights reserved. No part of this publication may be stored in a retrieval system or reproduced by any means whatsoever without the written consent of the publisher.10/2013

References: 1) Taddio et al, CMAJ 2005; 172(13): 1691–95. 2) Koh et al, Pediatric Anesthesia 2004; 14: 977–98. 3) LMX4 Summary of Product Characteristics, TGA August 2011. 4) Nestor, Journal of Drugs in Dermatology 2006, 5(7): 618–20. 5) Mezei M in Hsieh DS, ed. Drug permeation enhancement. New York, NY: Marcel Dekker Inc; 1994:171–98. 6) Kleiber et al, Pediatrics 2002; 100(4). 7) Emla Product Information March 2010. 8) Local AnGel RCH Melbourne, Consumer Health Information, 22 November 2002.

Made in the U.S.A. LMX4® is a registered trademark of Ferndale IP Inc. Rev 12/11. Supplied by Orion Pty Ltd, a Perrigo company. ABN 56009293136. 25–29 Delawney Street, Balcatta, WA 6021 AUSTRALIA

For more information visit www.LMX4.com.au

THE POWER OF...4

LMX4 Comparison

LIPOSOMAL LIGNOCAINE 4%

ENHANCED PENETRATION4,54

FASTEFFECTIVE FROM 30 MINUTES1

WELL TOLERATEDLOW INCIDENCE OF ERYTHEMA1

EFFECTIVEPAIN CONTROL1

Effective pain control with LMX41

• Pain reduced by 43% with LMX4 after 30 minutes1

• Pain control with LMX4 after 30 minutes is equivalent to emla after 60 minutes3

• LMX4® Pain control after 30 minutes is equivalent to emla® pain control after 60 minutes of application time

• Less skin blanching with LMX4*

VAS Pain Score

Incidence of skin

blanching (%)

Low levels of erythema with LMX41

• Erythema seen in only 2.9% of LMX4 patients1

Graph adapted from Taddio et al, 2005. Liposomal lidocaine to improve procedural success rates and procedural pain, double blinded randomised placebo controlled 142 patient study.

Effective from 30 minutes1

30mins

1 2 330

MINS60

MINS

30

20

10

0

10

20

30

40

50

60

70

*p=0.04

Graph adapted from Koh et al, 2004. Randomised double – blind comparison study of LMX4 and emla for topical anaesthsia in children undergoing IV insertion.

*

*

Skin redness

(%)

100

80

60

40

20

0

2.9%

LMX4®emla®

LMX4 is suitable for:• Skin needling and dermal rolling• Laser and IPL treatments – skin resurfacing• Tattoo art and tattoo removal• Simple excisions• IV canulation, blood sampling• Injectables and fillers• Hair removal• Piercings